HIND logo

VYOME HOLDINGS INC

HINDNASDAQ
🏆 #4779 by market capEarnings Nov 24US Equity
$1.72▲ $0.02 (+1.18%)
Market closed · at close
🔔
Track HIND
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.2%
7d▼ 2.0%
14d▼ 9.9%
30d▼ 16.9%
ytd▼ 50.0%
1y▼ 68.3%
🏦Market Cap
$12M
Small Cap
📈Revenue Growth (YoY)
-98.0%
Declining
📊Gross Margin
52.7%
Healthy
💵FCF Margin
—
⚖️P/S Ratio
92.0x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.62 – $1.75
52-Week Range
$1.70 – $6.56
Volume (shares)
8,013
Avg Volume (shares)
—
Shares Outstanding
7.0M
Next Earnings
2026-11-24

Fundamentals Snapshot

Annual Revenue
$319,714
Last Q Revenue
$26,955
P/E Ratio
—
P/S Ratio
92.0x
EPS (TTM)
$-3.51
Dividend Yield
—
Dilution (1yr)
+20172.4%
HIND logo

VYOME HOLDINGS INC

HIND
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$320K▼ −96.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
64.7%▲ +2.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$3M▼ −64.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$4M▼ −15.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
5.9M▲ +20172.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5M▲ +$5M YoY
StockOtter · stockotter.space

About VYOME HOLDINGS INC

Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

Business Wire·2d ago

Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND) ("Vyome"), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today congratulated its S

Business Wire·23d ago

Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND #ocularinflammation--Vyome Holdings, Inc. (Nasdaq: HIND) (“Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today

Business Wire·Sep 14

Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND #CFO--Vyome Holdings, Inc. (Nasdaq: HIND) (“Vyome” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for immuno-infla

Business Wire·Aug 25

Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND, “Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial re